-
Mashup Score: 2Berotralstat Reduces HAE Attacks in Phase 3 Trial - 3 year(s) ago
The FDA approved kallikrein inhibitor berotralstat for HAE in December 2020. A new study showed it’s superior to placebo in patients aged 12 years and older.
Source: MedscapeCategories: Latest Headlines, PediatricsTweet
-
Mashup Score: 2
Berotralstat (BCX7353) is a recently approved, oral, once-daily kallikrein inhibitor for hereditary angioedema (HAE) prophylaxis. In the APeX-2 trial, berotralstat reduced HAE attack rates over 24 weeks, with a favorable safety and tolerability profile.
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 3
Berotralstat (BCX7353) is a recently-approved, oral, once-daily kallikrein inhibitor for hereditary angioedema (HAE) prophylaxis. In the APeX-2 trial, berotralstat reduced HAE attack rates over 24 weeks, with a favorable safety and tolerability profile.
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0Berotralstat Improves Quality of Life in Hereditary Angioedema - Pulmonology Advisor - 3 year(s) ago
As part of the phase 3 APeX-2 study, researchers evaluated quality of life in adult patients with hereditary angioedema who received berotralstat.
Source: Pulmonology AdvisorCategories: Latest Headlines, PulmonologyTweet
FDA approved #plasma kallikrein inhibitor #berotralstat, in 2020, making it the first treatment available for the prevention of hereditary angioedema attacks in patients aged 12 years and up. Phase 3 trial results continue to show benefits. https://t.co/mBglu5VN5O